Trial · NCT07068542
Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer
NCT07068542, Not applicable, Recruiting, Zhejiang Provincial People's Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer. Trials, record NCT07068542. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07068542
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer
- NCT number
- NCT07068542
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 94 participants, estimated
- Lead sponsor
- Zhejiang Provincial People's Hospital
- Conditions
- Advanced Thyroid Carcinoma, Radioiodine-refractory Differentiated Thyroid Cancer, Poorly Differentiated Thyroid Carcinoma
- Interventions
- Sacituzumab Tirumotecan (SKB264) plus Tislelizumab, Sacituzumab Tirumotecan (SKB264)
- First posted
- 2025-07-16
- Last updated
- 2026-06-01
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Survival (OS) - ATC Cohort | From first dose until death from any cause (up to approximately 24 months after enrollment) | Overall survival is defined as the time from the first dose of study treatment to death from any cause in patients with unresectable or metastatic anaplastic thyroid carcinoma (ATC). |
| Primary | Progression-Free Survival (PFS) - PDTC and RAIR-DTC Cohorts | From first dose until documented disease progression or death (up to approximately 24 months) | Progression-free survival is defined as the time from the first dose of study treatment to the first documented radiographic disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first, in patients with PDTC and RAIR-DTC. |
| Secondary | Progression-Free Survival (PFS) - ATC Cohort | From first dose until documented disease progression or death (up to approximately 24 months) | Progression-free survival is defined as the time from the first dose of study treatment to the first documented radiographic disease progression per RECIST version 1.1 or death from any cause, whichever occurs first, in patients with anaplastic thyroid carcinoma (ATC). |
| Secondary | Overall Survival (OS) - PDTC and RAIR-DTC Cohorts | From first dose until death from any cause (up to approximately 24 months) | Overall survival is defined as the time from the first dose of study treatment to death from any cause in patients with PDTC and RAIR-DTC. |
| Secondary | Objective Response Rate (ORR) | Up to approximately 24 months | Objective response rate is defined as the proportion of patients achieving complete response (CR) or partial response (PR) as their best overall response according to RECIST version 1.1. |
| Secondary | Disease Control Rate (DCR) | Up to approximately 24 months | Disease control rate is defined as the proportion of patients achieving complete response (CR), partial response (PR), or stable disease (SD) according to RECIST version 1.1. |
| Secondary | Duration of Response (DoR) | Up to approximately 24 months | Duration of response is defined as the time from first documented objective response (CR or PR) until radiographic disease progression or death from any cause, whichever occurs first. |
| Secondary | Incidence of Treatment-Emergent Adverse Events (TEAEs) | From first dose until 30 days after last dose (SAEs up to 90 days) | Incidence, severity, and relationship of treatment-emergent adverse events graded according to NCI CTCAE version 5.0. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07068542
GET https://conductscience.org/api/trials/v1/NCT07068542/registered